Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ET 1402L1-CART

Next Previous
Drug Profile

ET 1402L1-CART

Alternative Names: AFP-CAR; AFP/ET1402; anti-AFP-ARTEMIS®2; ET-140203; ET140202; ET1402L1; ET1402L1-ARTEMIS®; ET1402L1-ARTEMIS®2

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eureka Therapeutics
  • Developer Eureka Therapeutics; First Affiliated Hospital-Xi'an Jiaotong University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Hepatoblastoma
  • New Molecular Entity No
  • Available For Licensing Yes - Liver cancer

Highest Development Phases

  • Phase I/II Liver cancer

Most Recent Events

  • 20 Jun 2023 Eureka Therapeutics terminates a phase I/II ARYA-1 trial in Liver cancer (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV), to direct the efforts to the pediatric study ARYA-2 (NCT04502082)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, In the elderly, Late-stage disease, In adults) in China (IV, Infusion)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Liver-cancer(Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top